Drug Trial Radar · NCT06100276
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Dec 30, 2030
Study completion Nov 30, 2031
Sponsor
- Lead sponsor
- UniQure Biopharma B.V.Industry
- Sponsor type
- Industry
- First posted
- Oct 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
AMT-162Drug
AMT-162, the investigational product (IP), is a nonreplicating, rep/cap-deleted, self-complementary Recombinant adeno-associated virus (rAAV) vector based on adeno-associated virus (AAV) serotype rh10 and contains complementary deoxyribonucleic acid (cDNA) encoding an artificial miRNA targeting the SOD1 gene.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ascending doses of intrathecally administered AMT-162 in Participants with SOD1-ALSTime frame: up to 5 years
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
University of California Irvine
Irvine, California
California Pacific Medical Center
San Francisco, California
Mayo Clinic Florida
Jacksonville, Florida
Winship Cancer Institute of Emory University
Atlanta, Georgia
Northwestern University Feinberg School of Medicine
Chicago, Illinois
University of Kansas Medical Center
Fairway, Kansas
Massachusetts General Hospital, Sean M. Healey and AMG Center for ALS Research
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Columbia University Irving Medical Center
New York, New York
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
Norrlands Universitetssjukhus
Umeå, Vasterbottens Ian, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.